 
Template version: January 30, 2020    
Title:  EEG to monitor  propofol anesthetic depth in infants and 
toddlers  
Short Title  EEG propofol depth young  children  
 
Study Drug  Propofol  
 
Sponsor:  
 The Children’s Hospi[INVESTIGATOR_66928]  
 22-019941  
Protocol Date:  
 October 10 , 2022  
Amendment 1 Date: November 8, 2022  
 Amendment 3 Date: June 13, 2023  
Amendment 2 Date:  January 17, 2023  Amendment 4 Date:  September 8, 2023  
 
Amendment 5 Date: December 11, 2023   
 
 
 
 
 
 
 
 
 
Study Principal Investigator  
[INVESTIGATOR_66929], MD  
Department of Anesthesiology and Critical Care Medicine  
The Children’s Hospi[INVESTIGATOR_6684]  
34th St and Civic Center Blvd, 9th floor  
 Philadelphia, PA [ZIP_CODE]  
Phone: 215 -590-1866 (Office)  
Email: [EMAIL_1305]  
    
   
ii 
 ii 
TABLE OF CONTENTS  
Table of Contents  ................................ ................................ ................................ ...................  ii 
Abbreviations and Definitions of Terms ................................ ................................ .............  iv 
Abstract  ................................ ................................ ................................ ................................ .. v 
Protocol Synopsis  ................................ ................................ ................................ .................  vii 
1 BACKGROUND INFORMATION AND RATIONALE  ................................ ................................ ....... 1 
1.1 INTRODUCTION  ................................ ................................ ................................ ................................ ..... 1 
1.2 RELEVANT LITERATURE AND DATA ................................ ................................ ................................ ..... 2 
1.3 COMPLIANCE STATEMENT  ................................ ................................ ................................ ....................  4 
2 STUDY OBJECTIVES  ................................ ................................ ................................ ..............................  5 
2.1 PRIMARY OBJECTIVE  ................................ ................................ ................................ ............................  5 
2.2 SECONDARY OBJECTIVES  ................................ ................................ ................................ .....................  5 
3 INVESTIGATIONAL PLAN  ................................ ................................ ................................ ....................  5 
3.1 GENERAL SCHEMA OF STUDY DESIGN  ................................ ................................ ................................ . 5 
 Screening Phase  ................................ ................................ ................................ ..............................  5 
 Study Interventional Phase  ................................ ................................ ................................ ..............  5 
EEG Monitoring  ................................ ................................ ................................ ................................ ...........  6 
 Laboratory Tests  ................................ ................................ .............  Error! Bookmark not defined.  
3.2 STUDY DURATION , ENROLLMENT AND NUMBER OF SITES ................................ ................................ ... 6 
 Duration of Patient Study Participation ................................ ................................ ..........................  6 
 Total Number of Study Sites/Total Number of Patients Projected  ................................ ..................  6 
3.3 STUDY POPULATION  ................................ ................................ ................................ .............................  6 
 Inclusion Criteria  ................................ ................................ ................................ ............................  6 
 Exclusion Criteria  ................................ ................................ ................................ ...........................  7 
4 STUDY PROCEDURES  ................................ ................................ ................................ ............................  7 
4.1 SCREENING PHASE  ................................ ................................ ................................ ...............................  7 
4.2 STUDY INTERVENTIONAL PHASE  ................................ ................................ ................................ ..........  7 
 EEG Recording  ................................ ................................ ................................ ...............................  7 
 Stimuli  ................................ ................................ ................................ ................................ .............  7 
4.3 PATIENT COMPLETION /WITHDRAWAL  ................................ ................................ ................................ . [ADDRESS_73167]  ................................ ................................ ................................ ............................  12 
5.3 SAFETY EVALUATION  ................................ ................................ ................................ .........................  12 
5.4 NON-EVALUABLE SUBJECTS  ................................ ................................ ................................ ...............  12 
6 STATISTICAL CONSIDERATIONS  ................................ ................................ ................................ .... 12 
6.1 PRIMARY ENDPOINT  ................................ ................................ ................................ ...........................  12 
6.2 SECONDARY ENDPOINTS  ................................ ................................ ................................ ....................  12 
    
   
iii 
 iii 
6.3 STATISTICAL METHODS ................................ ................................ ................................ ......................  12 
 Baseline Data  ................................ ................................ ................................ ................................  12 
 EEG SEF  ................................ ................................ ................................ ................................ ....... 13 
 Propofol Ce  ................................ ................................ ................................ ................................ ... 13 
 ................................ ................................ ................................ ................................ ................................ .... 14 
 Sample Size and Power  ................................ ................................ ................................ .................  14 
6.4 Safety Analysis  ................................ ................................ ................................ ..............................  14 
7 SAFETY MANAGEMENT  ................................ ................................ ................................ .....................  15 
7.1 CLINICAL ADVERSE EVENTS  ................................ ................................ ................................ ..............  15 
7.2 ADVERSE EVENT REPORTING  ................................ ................................ ................................ .............  15 
7.3 DEFINITION OF AN ADVERSE EVENT  ................................ ................................ ................................ .. 15 
7.4 DEFINITION OF A SERIOUS ADVERSE EVENT (SAE)  ................................ ................................ ...........  15 
 Relationship of SAE to study intervention  ................................ ................................ .....................  16 
7.5 IRB/IEC  NOTIFICATION OF SAE S AND OTHER UNAN TICIPATED PROBLEMS  ................................ ...... 16 
 Follow -up report  ................................ ................................ ................................ ...........................  16 
8 STUDY ADMINISTRATION  ................................ ................................ ................................ .................  16 
8.1 DATA COLLECTION AND MANAGEMENT  ................................ ................................ ............................  16 
8.2 CONFIDENT IALITY  ................................ ................................ ................................ ..............................  17 
8.3 REGULATORY AND ETHICAL CONSIDERATIONS ................................ ................................ ..................  17 
 Data and Safety Monitoring Plan  ................................ ................................ ................................ . 17 
 Risk Assessment  ................................ ................................ ................................ .............................  17 
 Potential  Benefits of Trial Participation  ................................ ................................ .......................  18 
 Risk-Benefit Assessment  ................................ ................................ ................................ ................  18 
8.4 RECRUITMENT STRATEGY  ................................ ................................ ................................ ..................  19 
8.5 INFORMED CONSENT AND HIPAA  AUTHORIZATION  ................................ ................................ ..........  19 
3.1.3  Individuals with Limited English Proficiency  ................................ ................................ ...............  19 
8.6 PAYMENT TO PATIENTS /FAMILIES  ................................ ................................ ................................ ...... [ADDRESS_73168]  
Context : (Background)  
Sevoflurane inhalation and propofol intravenous anesthesia are the mainstays of delivering 
general anesthesia in children. Propofol anesthesia in children is gaining popularity  due to 
fewer respi[INVESTIGATOR_11800], less post -operative nausea vomiting and emergence 
delirium, compared to sevoflurane. However, unlike sevoflurane, the pharmacodynamics of 
propofol is less studied  in infants  and toddlers, particularly the biomarker for propofol brain 
effect site concentration  (Ce), indicative of anesthetic depth. The lack of a real -time 
biomarker often results  in over - or under -dosing of propofol  in clinical practice . The goal of 
this study is to utilize electroencepha lography (EEG) as the biomarker of propofol effect site 
concentration and clinical anesthetic depth, thereby [CONTACT_66948].  
 
Objectives : (primary and important secondary objectives)  
Primary : In infants and to ddlers receiving propofol  anesthesia , EEG will be recorded while 
the patient  undergoes three stimuli  used to assess anesthetic depth  (placement of oral 
pacifier , electrical stimulation, and laryngoscopy). The EEG ind ex (spectral edge frequency -
SEF) where 50% of patient s do not respond to each of the three stimuli will be determined  
as the biomarker of propofol clinical anesthetic depth . 
Secondary : In the same cohort , the re gression  between EEG SEF and plasma propofol levels  
will be determined to assess relationship between EEG SEF and propofol Ce . 
 
Study Design :  
Sequential allocation prospective trial.  
 
Setting/Participants:  
The study will be performed at CHOP. Up to 150 patient s who are undergoing  procedures  
under general anesthesia will be enrolled to produce 120 evaluable patient s with 60 in each 
of two age groups (3 -12mo and 13 -24mo).  
 
Study Interventions and Measures :  
For each patient , up to three stimuli will be done in sequence ( placement of oral pacif ier, 
electrical stimulation, and laryngoscopy —a clinically required procedure ). Propofol dosing 
will be adjusted to achieve a target EEG SEF for each stimulus. EEG SEF is used as a 
biomarker of anesthetic depth. The response to the stimu lus and EEG SEF wil l be recorded, 
along with obtaining a 1ml blood sample. Obtaining the blood sample may not always 
coincide with the stimulus and up to three blood samples may be drawn per subject. 
Between different stimuli on the same patient , adjustments to propofol dosing may be 
    
   
vi 
 vi 
required to achieve a different SEF target. After each study patient , the response to the 
stimul us will be used to adjust the EEG SEF target for the next patient .  
At the end of the study, the median EEG SEF s (EEG SEF 50) for each of the three  stimul i 
will be determined. The propofol Ce that corresponds to each EEG SEF will be determined 
from a regression curve of SEF vs propofol plasma concentration obtained from 1ml of 
patient blood and measured in a pharmacodynamics laboratory . The study will only be 
performed by [CONTACT_66949].  
 
 page vii   
vii 
 PROTOCOL SYNOPSIS  
Study Title  EEG to assess propofol anesthetic depth in infants and toddlers  
Funder  Departmental funds  
Study Rationale  Sevoflurane inhalation and propofol intravenous anesthesia are the 
mainstays of delivering general anesthesia in children. Propofol 
anesthesia in infants  and toddlers  is gaining interest due to fewer 
respi[INVESTIGATOR_11800], less post -operative nausea vo miting and 
emergence delirium, compared to sevoflurane  anesthesia . However, 
the pharmacodynamics of propofol has not been well studied in 
infants  and toddlers , and there is no readily available method to 
monitor the depth of propofol anesthesia , which ofte n results  in 
over- or under -dosing of propofol. Anesthetic dosing and the 
resultant brain effect -site concentration (Ce) depend on the desired 
clinical endpoint during a procedure . In clinical practice , the three 
main endpoints  of anesthesia depth  are unco nsciousness , no 
response to surgical incision , and no response to laryngoscopy . 
Electroencephalography (EEG) can be used to monitor anesthetic 
depth during propofol anesthesia  in children and adults , as EEG 
parameters (spectral edge frequency -SEF) decrease predictably with 
increasing propofol Ce  and anesthetic depth . This study will use 
EEG SEF to monitor anesthetic depth in infants and toddlers  during 
three stimuli ( placement of oral pacifier , electrical stimulation, a nd 
laryngoscopy —a clinically required procedure ), which reflect the 
three endpoints of clinical anesthesia depth . The median EEG SEF 
where 50% of patient s do not respond to each of the three stimuli 
will be determined , along with the relationship between E EG SEF 
and propofol effect site concentration (Ce), as measured from 
plasma propofol levels  at the time the EEG SEF was recorded . 
Results from this study should  improve the safety and efficacy of 
propofol anesthesia  in infants  and toddlers  by [CONTACT_66950] a biomarker of  propofol  anesthetic depth, thereby [CONTACT_66951] - and under -dosing.   
Study Objective(s)  Primary  
In infants  and toddlers  receiving propofol anesthesia for a procedure  
determine the three EEG SEF s where 50% of patient s do not respond 
to the three stimuli ( placement of oral pacifier , electrical stimulation, 
and laryngoscopy —a clinically required procedure ). 
 page viii   
viii 
 Secondary  
In the same cohort , determine the dose -response relationship 
between EEG SEF and pr opofol Ce, as measured from plasma 
propofol levels.  
Study Design  
 Sequential allocation trial  using Dixon’s  up-down technique . To 
achieve the EEG SEF target , initial propofol dosing will be based on  
a published  age-based dosing table  used clinically at CHOP . The 
EEG SEF target for a specific stimulus will be determined by [CONTACT_66952] ’s response to that same stimulus. If the previous 
patient responded to the stimulus, then the current patient will have 
a lower SEF target for t he same stimulus. Conversely, if the 
previous patient did not respond to the stimulus, then the current 
patient will have a higher SEF target for the same stimulus.  
In the same patient , propfol dose adjustments may be needed 
between stim uli to achieve diff erent SEF targets. The patient  
response to stimulus and EEG SEF will be recorded, along with a 
1ml blood sample to determine propofol plasma level at a later date  
in the pharmacodynamic laboratory . The study will only be 
performed by [CONTACT_66953].  
Patient  Population  
key criteria for 
Inclusion and 
Exclusion:  Inclusion Criteria  
1) Children 3 to 24 month old  undergoing a procedure  
2) Planned laryngoscopy and endotracheal intubation or LMA 
placemen t for clinical care  
3) Planned  propofol anesthesia for anesthesia maintenance.  
4) ASA < III. 
5) Muscle relaxant not indicated per planned clinical care  for 
laryngoscopy/intubation . 
6) Anticipated  procedure  duration approximately < 2h40min  
 
Exclusion Criteria  
1) Patient s undergoing an emergency procedure  
2) Known severe neurological disease which might result in 
abnormal EEG SEF.  
3) Deformities of forehead (diff icult EEG sensor placement ). 
4) Known difficult airway.  
5) Allergy to propofol.  
 page ix   
ix 
 6) Attending anesthesiologist on record caring for patient pla ns to 
administer additional IV medication besides propofol during study 
phase.  
7) Currently on anti -seizure medication (might alter propofol 
pharmacodynamics) . 
Number Of Patient s  
 Up to 150 enrolled patient s to produce 120 evaluable patient s. 
Study Duration  Each patient ’s participation will last from start of anesthesia to the 
last study stimul us. 
Study Phases  
Screening  
 
Study  
Laboratory   From placement of second intravenous (IV) line or bolus of 
propofol (if IV is already present prior to induction) to the end of 
the last stimul us performed . Eligibility screening via reviewing 
procedure  schedule  and obtaining informed consent.  
 
The propofol plasma concent ration will be determined in the 
laboratory (Institutional Core  Lab at CHOP ) via batch processing of 
collected blood samples.  
Safety Evaluations  Patient  safety will be monitored by [CONTACT_20721] ( e.g. 
bronchospasm, laryngospasm) and vital signs ( e.g. hypotension).  
Statistical And 
Analytic Plan  The median EEG SEF (SEF 50) where half of the patient s do not 
respond to a particular stimulus will be determined for each of the 
three stimuli. For each stimulus, each SEF crossover pair (Yes to No 
response or vice versa) will be treated as a SEF pair and the mean 
and standard deviation of all SEF pairs will determine the median 
SEF [ADDRESS_73169] deviation. The propofol Ce that corresponds to 
each SEF will be determined through the  regression curve between 
plasma propofol concentration and SEF recorded at the time of the 
blood draw .  
DATA AND SAFETY 
MONITO RING PLAN The PI [INVESTIGATOR_66930]. The PI [INVESTIGATOR_66931] -site unanticipated, serious Adverse Events that are related 
to the research activity. Other unanticipated problems related to the 
research involving risk to patien ts or others will also be reported 
promptly.  In addition, an indep endent DSMB committee: Drs. 
Arjunan Ganesh, Raj Subramanyam , and Tori Sutherland , who are 
not involved in the study will monitor and review the study 
progress, patient  safety, and the accura cy and security of the 
 page x   
x 
 emerging data. Written reports will be filed using the eIRB system 
in accordance with the timeline below.  
 
   
[ADDRESS_73170] -site concentration  (Ce) 
depend on the desired clinical endpoint during the conduct of anesthesia and the procedure . 
The three main endpoints  of surgical anesthesia  are unconsciousness , no response to surgical 
incision , and no response to laryngoscopy . The dose to achieve the desi red anesthetic depth 
for each of these three endpoints is different; the dose to unconsciousness is less than the dose 
for lack of response to surgical incision  or laryngoscopy . Sevoflurane expi[INVESTIGATOR_66932] . The sevoflurane 
dose and corresponding Ce to achieve unconsciousness and block response to a procedure and 
laryngoscopy  are known in the pediatric population and differ between infants (3 -12 mo), 
toddler  (13-23 mo), and children (2 -12 years).8,[ADDRESS_73171] been established in adults and older 
children via laboratory measurements of propofol plasma concentration,10,11 they remain 
unknown in infants  and toddlers . 
Propofol dosing can be guided by [CONTACT_66954] (EEG) , which monitor s 
brain electrical acitivity and reflect s anesthetic depth . EEG parameters have been shown to 
change predictably with increasing propofol Ce in children and adults, and can be used to 
guide propofol dosing to the individual patient.12,13 In adult anesthesia and in pediatric practice 
at CHOP, intraoperative EEG monitoring is used to guide propofol dosing and assess 
anesthetic depth .14,3 Despi[INVESTIGATOR_66933] , commonly used EEG proprietary indices ( e.g., BIS, PSI) were developed in 
adults and not validated in young children. Non-proprietary EEG parameters, such as the 
spectral edge frequency (SEF) are valid in young children  under sevoflurane , but the 
relationship between EEG SEF and propofol Ce have not b een established in this young 
population . Furthermore, the relationship between EEG SEF and the three clinical endpoints 
(unconsciousness, lack of response to surgical incision , and lack of response to  laryngoscopy ) 
is also unknown in this age group.  
   
2 
 2 
The p roposed study will determine the pharmacodynamics of propofol on brain, 
respi[INVESTIGATOR_696] , and cardiovascular function at the three clinical endpoints in infants and toddlers  
receiving propofol anesthesia for a procedure . Brain, respi[INVESTIGATOR_66934]. The propofol Ce at each of the three 
clinical endpoints will be assessed by [CONTACT_66955] , which is 
equal to brain concentration at steady state . Although propofol may be combined with other 
agents (opi[INVESTIGATOR_2438], regional anesthesia, dexmedetomidine)  during anesthetic maintenance , many  
cases  utilize  propofol  as the sole agent  throughout  the entire  anesthetic  (e.g.,  GI endoscopy,  
bronchoscopy,  radiological  procedures).  The study only involves the induction period 
(induction to intubation), when propofol is commonly  given as the sole agent, without 
combination of regional anesthetics, opi[INVESTIGATOR_2438], or other agents. Studies have shown that 
anesthetic overdose is common during the induction period (9.3%) ,[ADDRESS_73172] benefit to the study patient by [CONTACT_66956] l overdose 
during the induction period.  
 
1.2 Relevant Literature and Data  
Propofol Anesthesia  
Propofol is FDA -approved for “ Induction of General Anesthesia Patients ≥ 3 years of age 
and Maintenance of General Anesthesia Patients ≥ 2 months of age” .16 Propofol use in the 
study does not involve a route of administration, dose, patient population, or other factor that 
significantly increases the risk (or decreases the acceptability of the risk) associated with the 
use. 
Propofol anesthesia consist of propofol bolus and infusion, which can be combined 
with regional anesthetic, opi[INVESTIGATOR_2438], dexmedetomidine, and/or muscle relaxant. For this study, 
only propofol will be administered during the study period  which lasts from placement of 
the second IV or first propofol dosing  until the end of the last s timul us In patient s with 
sevoflurane induction, sevoflurane will be washed out (patient  expi[INVESTIGATOR_66935]) prior to assessing EEG SEF and starting the first stimul ation . Sevoflurane 
washout typi[INVESTIGATOR_20187] 5 minutes. After the study period (end of last stimul us), the 
anesthetic team on record caring for the patient can administer other medications  as planned 
for the procedure.  
 
EEG Monitor  
The Masimo SedLine is a non-invas ive 4-channel EEG monitor that is 
portable, easy and fast to apply to the forehead, and displays process ed EEG. It is 
FDA -approved  for use with adults  and is widely used in  both the adult and pedia tric 
surgical population. We are interested in using the Spectral Edge Frequency ( SEF)—a 
non-proprietary EEG parameter , to assess anesthetic depth . The Masimo Sedline’s 
   
3 
 3 
usability and safety profile has been established through our stud ies (17-014608  and 
19-016071 ). The safety and ef ficacy of EEG SEF is not being evaluated as part of this 
study.  
 
EEG Parameters vs Anesthetic Dose  
EEG waveforms can be described using amplitude (how much  the EEG wave goes 
up and down) and frequency (how fast the wave goes up and down). Typi[INVESTIGATOR_897], with 
increased anesthetic dose, EEG amplitude increases and frequency decreases. Consequently, 
EEG spectral edge frequency (SEF) , the frequency where the majority (95%) of EEG power 
lies, decreases reliably with increased anesthetic dose down to age 3 months.17,18 During 
anesthesia and the procedure  SEF is calculated and displayed on Masimo EEG monitor 
every second. In older children very deep propofol anesthesia (high dose), deep propofol 
anesthesia (moderate dose), light propofol anesthesia (low dose), and emergence (residual 
drug not yet cleared) correspond to SEF of <5hz, 8 -11hz, 16 -18hz, and >20hz, 
respectively.12 In younger children  (3-24mo) , lighter and  deeper anesthesia correspond to 
SEF 11.4 -14.3hz and 8.1hz, respectively.18 
 
EEG SEF vs Responses to Stimuli  
During anesthesia and the procedure , anesthet ic depth is assessed by [CONTACT_66957]. The key stimuli to assess a response in adults and children include : 1) name 
[CONTACT_3379]/shake -and-shout (assess consciousness); 2) electric al stimulation  (a non -injurious 
substitute for surgical incision ), and 3) laryngoscopy (assess readiness for intubation) .9,19,20 
Since responses to name [CONTACT_3379]/shake -and-shout are not applicable to infants  and unreliable 
in toddler s, the response to placement of oral pacifier  is used to assess consciousness  
instead . The refore,  the three stimuli used in this study are: 1) placement of oral pacifier , 2) 
electric al stimulation, and 3) laryngoscopy —a clinically required procedure . Place ment of 
oral pacifier involves placing a soft pacifier inside the patient ’s mouth . Electric al stimulation 
is used to assess neuromuscular function  but in our study will also be used as a non -injurious 
substitute for surgical incision . Laryngoscopy  is clinically required to place the breathing 
tube, regardless of the study . Since placement of the oral pacifier and electrical stimulation 
are stimul i that are not part of standard clinical care, only the investigators on the study will 
be performing the stimulations .  
A positive response to each of the three stimuli is the occurrence of any of the 
following: swallowing, sucking, eye opening, facial movement , gross limb movement 
towards the source of stimulus and additionally for laryngoscopy : breath -holding, closure of 
the vocal cords , and coughing.19-21 These responses typi[INVESTIGATOR_66936]. If a positive response is observed, the stimulus is 
stopped. It is likely that a different anesthetic depth and SEF target is needed for each of the 
three stimuli , which can be achieved by [CONTACT_66958]. From clinical experience , 
in infan ts and toddlers , consicousness, response to surg ical incision , and response to 
   
4 
 4 
laryngoscopy correspond to SEF of approximately >15, 10 -15, < 10hz, respectively.[ADDRESS_73173] 50 years,  it has been 
used in anesthesia research to determine the median effective dose (ED50) for other 
anesthetics and stimuli, including the three indicators of anesthetic depth  proposed in this 
study.22-24 This sequential allocation trial method can determin e pharmacodynamics using a 
smaller number of patient s than other methods .24  
 
EEG vs Propofol Ce  
At steady state propofol plasma concentration and  brain  Ce are equa l. This can be 
achieved in approximately 4 -6 minutes after a dose change (2-3 times  blood to brain half-
time kinetic constant of 2 minutes) and confirmed with stable EEG SEF.16,[ADDRESS_73174] imuli, to avoid residual sevoflurane’s effects on the brain and 
EEG. Sevoflurane washout is accomplished by [CONTACT_66959] , which is how sevoflurane anesthesia is discontinued in clinical 
care at the end of the procedure . Sevoflurane concentration measure d from the expi[INVESTIGATOR_66937]. Sevoflurane washout is complete when expi[INVESTIGATOR_66938] < 0.2%. Propofol infusion and EEG monitoring will start prior to comple ting 
sevoflurane washout in order to maintain the anesthe tic state while switching from 
sevoflurane to propofol.  
Several studies used propofol plasma concentration to validate the accuracy of 
population pharmacokinetic models in estimating propofol Ce , including two studies in 
older children.4,26-[ADDRESS_73175] study found an inverse linear relationship between EEG  BIS 
index ( a proprietary  EEG index ) and propofol plasma concentration in children > 6 years 
old.28 The seco nd study found that propofol plasma concentration 3.9 mcg/ml corresponded 
to EEG BIS index of 50 in children 4 -11 years old.26 There are few studies looking at the 
association of EEG parameters and propofol plasma concentration in infants  and young 
toddlers .  
 
1.3 Compliance Statement  
This study will be conducted in full accordance with all applicable Children’s Hospi[INVESTIGATOR_5765] 45 CFR 46, 21 CFR Parts 50, 54, 56, 312, 314 and 81 2 and the Good 
   
5 
 5 
Clinical Practice: Consolidated Guideline approved by [CONTACT_66960] (ICH). Note: Only include the sections of Title 21 if the study is regulated by 
[CONTACT_1622]. Only include ICH compliance if the study will actual ly comply with these 
requirements . All epi[INVESTIGATOR_48478].  
 
The investigators will perform the study in accordance with this protocol, obtain consent, 
and report unanticipated problems involving risks to patient s or others in acco rdance with 
The Children’s Hospi[INVESTIGATOR_66939]. Collection, recording, and reporting of data will be accurate and will ensure 
the privacy, health, and welfare of research patient s during and aft er the study.  
 
2 STUDY OBJECTIVES  
2.1 Primary Objective  
In patients  receiving propofol anesthesia for a procedure , determine the three EEG SEF s values  
where 50% of patient s do not respond to each of the three stimuli : placement of oral pacifier , 
electrical stimulation, and laryngoscopy —a clinically required procedure . 
 
2.[ADDRESS_73176] site concentration (Ce), at each EEG SEF  
for placement of oral pacifier, electrical stimulation, and laryngo scopy, as calculated from the 
regression between plasma propofol levels and EEG SEF recorded at the time of the blood 
draw .   
 
 
3 INVESTIGATIONAL PLAN  
3.1 General Schema of Study Design  
This is a prospective interventional study to determine EEG SEF and propofol  Ce during 
stimuli.   
 
 Screening Phase  
Potential patient s will be identified from the procedure  schedule using the study inclusion  
and exclusion criteria. Informed consent  will be obtained prior to any study related 
procedures being performed.   
 
 Study Interventional Phase  
The study interventional phase will occur during the intraoperative period from  after 
placement of second IV line or bolus of propofol (if IV line is pr esent prior to induction) to 
the last stimu lus.  
   
[ADDRESS_73177] stimul us.  
Stimuli  
 At steady -state EEG SEF , two rese arch stimul i (placement of oral pacifier  and electrical 
stimulation ) will be performed by [CONTACT_1704](s). The third stimul us, 
laryngoscopy —a clinically required procedure , will be performed by [CONTACT_66961] .  
 
Propofol dosing  
Adjustment to p ropofol infusion and dosing is considered standard of care  and is needed to 
achieve different anesthetic depth s and SEF target s for different stimuli.  As described in the 
study flowchart below, if current SEF is below  target SEF, then propofol dose will be 
decreased. Conversel y, if current SEF is above target SEF, then propofol dose will be 
increased.  
 
Second IV Placement  
An IV sep arate from the p ropofol infusion line will be placed in order to draw blood 
samples  to evaluate propofol plasma concentration . Often the second IV will also be 
clinically indicated regardless of study status.  If the second IV line is unable to be placed, a 
butterfy needle may be used to draw a single sample.  
Blood Sample Collection  
Up to three 1ml blood sample s, for a total of 3m l, will be collected  during the study 
interventional phase.  
3.2 Study Duration, Enrollment and Number of Sites  
 Duration of Patient  Study Participation  
The study duration for each patient  will be the day of the procedure  during the intraoperative 
period.  
 
 Total Number of Study Sites/Total Number of Patients  Projected  
The study will only be conducted at CHOP. It is expected that approximately 150 patient s 
will be enrolled to produce 120 evaluable patient s, 60each in the 3-12mo and 13 -24mo  age 
groups . 
 
3.3 Study Population  
 Inclusion Criteria  
1) Children 3 to 24 mo nth old undergoing a procedure . 
   
7 
 7 
2) Planned laryngoscopy and endotracheal intubation  or laryngeal mask airway  (LMA ) 
placement  for clinical care.  
3) Planned propofol anesthesia for anesthesia maintenance  during study period . 
4) ASA < III. 
5) Muscle relaxant not indicated per planned clinical care  for laryngoscopy/intubation  or 
LMA . 
6) Anticipated procedure duration approximately < 2h40min  
 
 Exclusion Criteria  
1) Patients undergoing an emergency procedure . 
2) Known severe neurological disease which might result in abnormal EEG SEF . 
3) Deformities of forehead (difficult EEG sensor placement).  
4) Known difficult airway.  
5) Allergy to propofol.  
6) Attending anesth esiologist on record caring for patient plans to administer additional IV 
medication besides propofol during study phase.  
7) Currently on anti -seizure medication (might alter propofol pharmacodynamics) . 
 
Patients  that do not meet all of the enrollment criteri a may not be enrolled. Any violations of 
these criteria must be reported in accordance with IRB Policies and Procedures.   
 
4 STUDY PROCEDURES  
4.1 Screening Phase   
Procedures below will be performed during the screening phase.  
• Informed Consent/HIPAA authoriza tion 
• Medical Record Review  
 
4.2 Study Interventional Phase  
 EEG Recording   
After anesthesia  induction, Masimo Sedline EEG will be applied to the patient ’s 
forehead  and recording will continue until after the last stimulus .  
 Stimuli  
Two research stimul i: placement of oral pacifier  and electrical stimulation  will be performed 
by [CONTACT_1704]. The third  stimulus, laryngoscopy, will be performed by [CONTACT_66962]. The stimulus will be performed after the 
patient  has achieved steady state at target EEG SEF, as described in the flowchart below.  
The response to each of the three stimu li (Yes/No) will be recorded. Given time contraints, 
not all three stimuli may be performed  on each patient . Each research stimulus may only be 
   
8 
 8 
applied once to each patient . The flowchart below shows the study procedures . Details of the 
stimuli are below:  
1) Placement of oral pacifier  involves placing a soft pacifier inside the patient’s mouth . 
2) Electric al stimulation  is typi[INVESTIGATOR_66940] e to assess neuromuscular function . 
3) Laryngoscopy  is done prior to intubation (placement of breathing tube) and is considered 
a clinical ly-required procedure for all patient s. 
 
 
 
 
4.3 Patient  Completion/Withdrawal  
Parents or caregivers may withdraw the patient  from the study at any time without prejudice 
to their care. They may also be discontinued from the study at the discretion of the 
responsible attending anesthesiologist on record and/or study i nvestigator due to unforeseen 
circumstances ( unable to establish IV access, lack of time, unable to achieve steady state 
SEF, etc…) . The placement of the second IV will occur alongside routine clinical care. It 
will not result in additional anesthesia time as standard car e is able to continue while the IV 
is being placed .  If the study i nvestigator becomes aware of any serious, related adverse 
events after the patient  completes or withdraws from the study, they will be recorded in the 
source documents and on the CRF.  
 

   
[ADDRESS_73178] Review  
• PHI: MRN, name, element of dates  including  birth date and service dates  
• Demographic  
• Anesthetic record s 
• Medication list  
• Surgical records  
• Post operative recovery records  
• Expected procedure duration  and procedure type 
• ASA status  
 
 EEG Monitoring  
The study team will assess skin integrity prior to applying the EEG sensor. After anesthesia 
induction , the Masimo EEG sensor will be placed on the forehead and connected to the EEG 
monitor. EEG monitoring  for the study will continue until laryngoscopy . The Masimo EEG 
monitor will automatically calculate and display EEG SEF values.   
 Propofol Dosing  
Propofol will be admin istered via an infusion pump with initial dosing based on a 
published dosing table  used in CHOP  clinical practice (table 1).[ADDRESS_73179] two to three stimuli applied in 
sequence ( placement of oral pacifier , electrical stimulus, and laryngoscopy ). Based on 
responses to each stimulus, the SEF target and propofol dose may be adj usted for the next 

   
[ADDRESS_73180] stimuli, to avoid residual sevoflurane’s effects on 
the brain and EEG. This can be done by [CONTACT_66963][INVESTIGATOR_66941]. Sevoflurane washout is complete when end tidal 
sevoflurane conc entration < 0.2%. Propofol infusion and EEG monitoring will start prior to 
completing sevoflurane washout.  
Placement of oral pacifier   
After anesthesia induction , sevoflurane washout  (if applicable) , and EEG SEF at the target 
for placement of oral pacifier , an oral pacifier  will be placed in the patient’s mouth . The oral 
pacifier  will be withdrawn if there is a positive response (defined in section 5.1.5 ) or when 
5 seconds has elapsed .  
Electrical stimulus  
The study team will assess forearm skin i ntegrity prior to applying the nerve stimula tor 
electro des. After sevoflurane washout (if applicable) and EEG SEF at the target for 
electrical stimulus , a nerve stimulator  (Halyard EZstim , Halyard Health Inc)  will be initiated 
at 50hz 30mA for up to 15 seconds.30 The electrical stimul us will  stop if there is a positive 
response (defined below) or when 1 5 seconds has elapsed .  
Laryngoscopy   
After sevoflurane washout (if applicable) and EEG SEF at the target for laryngoscopy , 
laryngoscopy will be performed by [CONTACT_66964] . This 
will mark the end of the stimuli interventions. If no response to laryngoscopy is elicited, the 
anesthesia team on record may choose to intubate the patient or adm inister additional 
medications. If a positive response to laryngoscopy is elicited, the anesthesia team on record 
may choose to stop laryngoscopy and/or administer additional medications  such as 
neuromuscular  relaxant . 
 
Responses to the stimuli will be rec orded . The patient  will be monitored closely by [CONTACT_66965] s. Study interventions will occur simultaneously with routine 
clinical anesthesia and surgical care; therefore, there will be no additional time under 
anesthesia from  this study. Not every patient will have all three stimuli performed and some 
patients may have only one research stimuli performed . Study procedure s will be stopped 
once all standard , clinical care pr eparation for surgery is completed.  
The same stimulus will not be applied twice to the same patient. The patient’s study 
involvement will conclude once laryngoscopy has been performed on the patient  and blood 
   
11 
 11 
draw (if applicable) has been performed . The remainder of the anesthetic will be per routine 
care.  
 
 Responses to Stimuli  
A positive response to the stimuli  described above  is occurrence of any of the 
following: swallowing, sucking, eye opening, facial movement , gross limb movement 
towards the source of stimulus , and additionally for laryngoscopy , breathi ng-holding, 
closure of vocal cords , and coughing.  These responses typi[INVESTIGATOR_66942] . Patient  response (Yes/No) will be recorded 
for each stimulus applied.   
 
 Blood collection  
Before a  stimulus is applied, the SEF value and vital signs will be recorded and a 1ml blood 
sample will be obtained  (not from the propofol infusion IV line ). Up to three blood samples 
may be collected s..  
 Dixon Up -Down Technique  
Using Dixon  up-down technique, the  current patient’s response to stimulus at a SEF 
target will determine the next patient’s SEF target  for the same stimulus , thus forming the 
sequential design method. Using placement of oral pacifier  as an example  and SEF step size 
of 2hz, patient #1 start s at SEF target of 18hz and has a positive response to placement of 
oral pacifier . Patient #[ADDRESS_73181] a decrement of SEF target by [CONTACT_66966] 16hz (18 
minus 2) for the same stimulus. If patient #2 also has a positive response to placement of 
oral p acifier , then patient #[ADDRESS_73182] a further decrement in SEF target by [CONTACT_66966] 
14hz (16 minus 2). If patient #3 has a negative response  to placement of oral pacifier , then 
patient #4 will increase SEF target one step to 16hz (14 plus 2). This con tinues until there 
are consecutive crossovers ( typi[INVESTIGATOR_66943]-down -up-down…), whereby [CONTACT_66967].24 Since each stimulus is of 
varying intensity, it’s expected that e ach of the [ADDRESS_73183] its own Dixon up -down  
calculated SEF target.  
 
 Achieving SEF target  
The EEG SEF targets will be different  for each of the three stimuli  (e.g., the propofol 
dose and anesthetic depth to block response to placement of oral pacifier  is less than for 
electrical stimulation and laryngoscopy ). Based on our c linical experience,  the initial SEF 
targets for the first patient will be 20, 14, and 10hz for placement of oral pacifier , electrical 
stimulation, and laryngoscopy , respectively. For the same stimulus, t he subsequent patient’s 
target SEF will be determined  by [CONTACT_66968]’s response to th at stimulus, as 
   
12 
 12 
described in the section Dixon up -down technique . After sevoflurane washout (if applicable) 
and the propofol infusion dose and SEF are constant for 5 minutes, to ensure equilibration  
between propofol  brain Ce and plasma concentration, the stimulus will be applied as 
described in the section EEG vs Propofol Ce.  If current SEF is higher than target SEF, 
additional propofol ( 0.5-2mg/kg boluses and /or 10-20% increases in propfol  infusion rate) 
can be given to decrease SEF closer to target SEF. Conversely, if current SEF is lower than 
target SEF, propofol infusion rate can be decreased 10 -20% or temporarily paused to 
increase SEF to target SEF.  
 
5.[ADDRESS_73184]  
Blood samples will be sent to  Institutional Core  laboratory  at CHOP for batch 
processing to measure  plasma propofol concentration.    
 
5.3 Safety Evaluation  
Patient  safety will be monitored  by [CONTACT_20721], vital signs, and patients ’ response.   
 
5.4 Non-evalua ble Subjects  
Non-evaluable subjects include 1) patient received IV medication other than propofol and 
midazolam from the anesthesia team during study phase, 2) unable to get EEG SEF reading 
during study phase, or 3) unable to decrease expi[INVESTIGATOR_66944] ≤ 0.2% during study 
period.  
 
6 STATISTICAL CONSIDERATIONS  
6.1 Primary Endpoint  
Three EEG SEF 50 values corresponding to where 50% of patients do not respond to 1) 
placement of oral pacifier  EEG SEF 50, 2) electrical stimu lation  EEG SEF 50, and 3) 
laryngoscopy  EEG SEF 50.  
 
6.[ADDRESS_73185] descriptive 
summaries (e.g.  means and standard deviations for continuous variables such as age and 
percentages for categorical variables such as gender).  
 
   
13 
 13 
 EEG SEF  
The median EEG SEF (SEF 50) for a stimulus is the SEF where half the patients do not 
respond to that particular stimulus. SEF 50 will be determined for each of the three stimuli  for 
the 3 -12 mo and 13 -24 mo age groups . For each stimuli, each SEF crossover pair ( Yes to No 
response or vice versa) in the Dixon’s up -down  respons e will be treated as a SEF pair and 
the mean SEF [ADDRESS_73186] deviation  of the SEF pairs will be determined . See figure 
below for example of Dixon’s up -down method and determination of SEF 50 for 
laryngoscopy. X axis represents sequential patients  #1 to # 30, Y axis represent SEF levels. 
Each blue (Yes response) and red (No response) dot represent a patient. The orange bars on 
the X axis represent crossover pairs, used to calculate SEF 50. 
In the laryngoscopy example below , the mean SEF [ADDRESS_73187] deviation is 
1.83hz, derived from crossover points: 5, 9, 9, 9, 9, 9, 7, 7, 5, 7, 7, 7, 7, 11, 11, 11, 9, 9hz.  
 
 
  Propofol Ce  
The propofol plasma concentration  will be determined by [CONTACT_66969]. A 
regression curve will be determined from the plot of plasma propofol concentration vs SEF 
at the time the blood was drawn for the propofol level . At steady state, plasma propofol and 
propofol Ce are equal . The propofol Ce corresponding to each SEF 50 will be calculated from 
the regression. There will be two regression curve s, one  for the 3 -12 mo age group and the 
other for the 13-24 mo age group. See figure below for example of Propofol Ce vs SEF 
curve for on e age group; x -axis is SEF and y -axis is propofol Ce.  

   
[ADDRESS_73188] a sample size of 10 -30 for 
each stimulus.23 Hammer et al. used the Dixon up -down  method to determine the propofol 
median effective dose (ED50) to prevent movement in children undergoing gastro -
endosco pe insertion with a sample size of 12.31 Endoscope insertion is a procedure similar to 
laryngoscopy . We propose a sample size of 30 for each stimulus  for each age group . 
Because only one or  two stimuli can be performed per patient  within the proposed study 
time ( e.g., placement of oral pacifier  before laryngoscopy , or nerve stimulation before 
laryngoscopy ), the required sample size  of subjects for each age group needs to be up to 60, 
for a towal of [ADDRESS_73189] the EEG SEF.   
 
6.4 Safety Analysis  
During the study period, adverse events (AE) are defined as:  
1- Oxygen desaturation (< 85%  for more than 30 seconds) . 
2- Hypotension (mean arterial pressure <  40 mmHg for 3 -12 mo and < [ADDRESS_73190] two measurem ents). 
3- Bradycardia (HR < 60 bpm  for more than 30 seconds ) will be recorded for all patient s.  
4- Overhead call for emergency help.  
5- Laryngospasm requiring intervention .  

   
15 
 15 
 
AE incidence will be summarized along with the corresponding SEF values during the 
occurrence.  
 
7 SAFETY MANAGEMENT  
7.1 Clinical Adverse Events  
Clinical adverse events (AEs) will be monitored throughout the study.  
 
7.2 Adverse Event Reporting  
Unanticipated problem s related to the research involving risks to patient s or others that 
occur during the course of this study (including SAEs) will be reported to the IRB in 
accordance with CHOP IRB SOP 408: Unanticipated Problems Involving Risks to Patient s. 
AEs that do not  meet prompt reporting requirements will be summarized in narrative or 
other format and submitted to the IRB at the time of continuing review  (if continuing 
reviews are required), or will be tracked and documented internally by [CONTACT_66970] (if continuing reviews are not required) .   
 
7.[ADDRESS_73191] medical occurrence in a patient  who has received the 
study  intervention  procedure s: placement of oral pacifier  and electrical stimu lation . The 
occurrence does not necessarily have to have a causal relationship with the treatment. An 
AE can therefore be any unfavorable or unintended sign, symptom, or disease temporally 
associated with the use of study required procedure , whether or not  considered related to the 
study procedure . 
All AEs (including serious AEs) will be noted in the study records and on the case report 
form with a full description including the nature, date and time of onset, determination of 
non-serious versus serious, in tensity (mild, moderate, severe), duration, causality, and 
outcome of the event.  
 
7.4 Definition of a Serious Adverse Event (SAE)  
An SAE is any adverse drug experience occurring at any dose that results in any of the 
following outcomes:  
• death,  
• coma,  
• heart, lung, or brain demage,   
• requires unanticipated inpatient hospi[INVESTIGATOR_6929],  
• a persistent or significant disability/incapacity, or  an important medical events  that may 
not result in death, be life -threatening, or require hospi[INVESTIGATOR_3767] a 
   
16 
 16 
serious adverse event when, based upon appropriate medical judgment, they may 
jeopardize the patient  and may require medical or surgical intervention to prev ent one 
of the outcomes listed in this definition.  
 
 Relationship of SAE to study intervention  
The relationship of each SAE to the study intervention should be characterized using one of 
the following terms in accordance with CHOP IRB Guidelines: definitely , probably, 
possibly, unlikely or unrelated.  
7.5 IRB/IEC Notification of SAEs  and Other Unanticipated Problems  
The Investigator will promptly notify the IRB of all on -site unanticipated, serious Adverse 
Events that are related to the research activity. Other unanticipated problems related to the 
research involving risk to patient s or others will also be reported promptly. Written reports 
will be filed using the eIRB system and in accordance with the timeline below. External 
SAEs that are both unexpected and re lated to the study intervention will be reported 
promptly after the investigator receives the report.  
Type of Unanticipated 
Problem  Initial Notification  
(Phone, Email, Fax)  Written Report  
Internal (on -site) SAEs  
Death or Life Threatening  24 hours  Within 2 calendar days  
Internal (on -site) SAEs  
All other SAEs  7 days  Within 7 business days  
Unanticipated Problems 
Related to Research  7 days  Within 7 business days  
All other AEs  N/A Brief Summary of important 
AEs may be reported at time 
of continuing review  
 
 Follow -up report  
If an SAE has not resolved at the time of the initial report and new information arises that 
changes the investigator’s assessment of the event, a follow -up report including all relevant 
new or reassessed information (e.g., concomitant medication, medical history) should be 
submitted to the IRB. The investigator is responsible for ensuring that all SAE are followed 
until either resolved or stable.  
 
8 STUDY ADMINISTRATION  
8.1 Data Colle ction and Management  
Minimal identifiable information might be printed and recorded on paper for study eligibility 
clarification, study data collection, data validation, and consenting document.  Any paper 
documents will only be accessible to approved CHOP staff and will be kept in the locked 
   
17 
 17 
research office when not in use.  Any un -needed paper data that has identifiable information will 
be shredded as soon as possible.  
• Confidentiality: A master list containing PHI and patient  ID number will be kept in 
REDCap. PHI will be labled as “Identifier” in REDCap, so data could be exported 
as coded dataset for analysis.  
• Security: Data will be kept in the REDCap database and CHOP secure servers.   
8.[ADDRESS_73192] privacy and that 
the Investigator and other site personnel will not use such data and records for any purpose 
other than conducting the study.  The investigator will obtain a data use agreement between 
the provider (the PI)  of the data and any recipi[INVESTIGATOR_66945] a limited 
dataset (PHI limited to dates and zip codes).  
8.[ADDRESS_73193] an independent DSMB  committee : Drs. Arjunan Ganesh , Raj 
Subramanyam , and Tori Sutherland , who are not inv olved in this study. The DSMB 
committee  will meet before every continuing review or as needed to monitor and review the 
study progress, patient  safety, and the accuracy and security of the emergi ng data. During 
the study period, each patient  will be monitored for any adverse events or safety concerns  by 
[CONTACT_1697] s. Additionally, the PI [INVESTIGATOR_66946], subject safety, 
and the accuracy and security of the emerging data . 
 
 Risk Assessment  
The assessment to support the study involving greater than minimal risk but  presenting the 
propect of direct benefit to the individual subjects to qualify for approval under 45 CFR  
§46.40 5. The study protocol  required  procedures are placement of oral pacifier , electrical 
stimul us, laryngoscopy, and blood draws from a n IV.   
• Risks of placement of oral pacifier : Minimal . 
• Risks of electrical stimulation: Minimal (redness  and irritation to the skin from the 
adhesive on the electrodes , which should self -resolve within 24  hours ).  
• Risks of laryngoscopy: Coughing, breath -holding, vocal cord closure, and arterial 
desaturation. Laryngoscopy is a clinically necessary procedure that will be performed 
regardless of study. Patients m ay have increased risk of vocal cord closure because they 
will not receive a muscle relaxant for intubation, although laryngoscopy is often done 
without muscle relaxant in standard clinical care (55% of the time). Furthermore, a 
muscle relaxant for intubat ion is contraindicated for many patients in our study due to 
   
18 
 18 
the type of  procedure . Patients undergoing a procedure who are not expected to require 
muscle relaxant will be enrolled. Patients may experience temporary arterial desaturation 
during anesthesia care related to coughing and breathholding during induction , 
emergence , and recovery.  Laryngoscopy is not a study -related risk and will occur 
regardless of study participation.  
• Risks of blood draws: Minimal. Blood will be collect ed while the patient  is anesthetized.  
The investigator will adhere to t he NIH "Guidelines for Limits of Blood Drawn for 
Research Purposes"  and no more than 5 mL/kg will be drawn for research purposes  in a 
single day.  
 
The study period occurs before the procedure and any surgical stimulation, there fore there  is 
no risk associated with withholding regional anesthetic, opi[INVESTIGATOR_2438], or dexmedetomidine. 
Propofol is often given as the sole agent during the induction period. There may be a small 
risk associated wit h withholding muscle relaxant prior to laryngoscopy, The potential risks 
include coughing, movement, and laryngospasm, although these risks are far less with 
propofol . 
Study interventions will happen concurrenly with routine clincal care; there will be no 
additional anesthesia time.  
The risks associated with the use of EEG are no more than minimal. It is possible that the 
adhesive sensor may irritate the skin. Sensor sites will be checked for possible irritation.  
 
 Potential Benefits of Trial Participation  
There may be  direct benefits to the study participant s, since they will have EEG monitoring 
during the study period making them less likely to experience isoelectric EEG and 
associated hypotension . Isoelectric EEG is common in young children under anesthesia , 
63% at CHOP32 and 32% worldwide15. Isoelectric EEG is associa ted with intraoperative 
moderate and severe hypotension , preventable critical events that increase morbidity.[ADDRESS_73194] benefits to future patients  include: 1) improved accuracy of propofol dosing in 
infants  and toddlers;  2) safer propofol anesthesia care - lower incidence of  hypotension from 
over-dosing, and lower incidence of insufficient anesthesia from propofol under -dosing; and  
3) better efficacy - faster emergence and recovery from less  propofol  over-dosing . 
 
 Risk -Benefit Assessment  
This study involves no more than a mino r increase above minimal risk.  There are direct 
benefits to study participant s to have EEG monitoring to prevent isoelectric EEG and 
associated hypotension, and indirect benefits to future patients for preventing propofol 
under - and over -dosing . 
 
   
[ADDRESS_73195]. Investigator  will only 
approach permissible patient s.  
 
8.5 Informed Consent and HIPAA Authorization  
Patients’s  parent(s)/legal guardian(s) will be approached by [CONTACT_66971] a private setting , such as a private exam room . The investigation team will 
make a good faith effort to obtain consent the day prior to the procedure . The primary aim, 
risks, benefits and study procedures for the study will be explained and the parent(s)/legal 
guardian(s) will have ample time and opportuni ty to ask questions. It will be reiterated that 
the decision to participate or decline to participate in the study will have no bearing on their 
medical care.  
 
Per institutional policy, the investigators intend to obtain electronic "written" consent via 
REDCap, the following criteria apply  
• A valid electronic signature [CONTACT_66975].  
• The patient  will receive an electronic copy of completed consent and HIP AA 
authorization form by [CONTACT_66972].  
If unable to obtain consent electronically , a paper copy of the consent form will be signed  and 
uploaded to the study’s REDCap.  
Individuals with Limited English Proficiency  
The short form consent process will be utilized for enrollement of limited English 
proficiency patients.  The investigator is familiar with the IRB's guidance on the short form 
consent process, i.e. the use of interpreters, the requirement of a witness, and  the required 
signing of a study summary document and a short form consent form by [CONTACT_66973] . If REDCap electronic consent is used for LEP patients  and an in -person interpreter 
is not available,  phone interpretation through  Language Services A ssociates will be u tilized 
as outlined in the Office of Research Compliance guidance and no study procedures will 
take place until all electronic signatures have been obtained.  
 
8.6 Payment to Patient s/Families  
There will be no payments to families.   
 
9 PUBLICA TION  
Publication in a peer -reviewed journal will be pursued after completion of the study.  
Only aggregate data without individual identifiable information will be published.  
 
   
20 
 20 
10 REFERENCES  
1. Brioni JD, Varughese S, Ahmed R, Bein B. A clinical review of inhalation 
anesthesia with sevoflurane: from early research to emerging topi[INVESTIGATOR_1102]. Journal of 
anesthesia. 2017;31(5):764 -778. 
2. Chidambaran V, Costandi A, D’Mello A. Propofol: a review of its role  in pediatric 
anesthesia and sedation. CNS drugs. 2015;29(7):543 -563. 
3. Morse J, Hannam JA, Cortinez LI, Allegaert K, Anderson BJ. A manual propofol 
infusion regimen for neonates and infants. Pediatric Anesthesia. 2019;29(9):907 -
914. 
4. Sepúlveda P, Corti nez L, Sáez C, Penna A, Solari S, Guerra I, Absalom AR. 
Performance evaluation of paediatric propofol pharmacokinetic models in healthy 
young children. British journal of anaesthesia. 2011;107(4):593 -600. 
5. Oberer C, von Ungern -Sternberg BS, Frei FJ, Erb TO. Respi[INVESTIGATOR_66947]. The 
Journal of the American Society of Anesthesiologists. 2005;103(6):1142 -1148.  
6. Chandler JR, Myers D, Mehta D, Whyte E, Groberman MK, Montgome ry CJ, 
Ansermino JM. Emergence delirium in children: a randomized trial to compare total 
intravenous anesthesia with propofol and remifentanil to inhalational sevoflurane 
anesthesia. Pediatric Anesthesia. 2013;23(4):309 -315. 
7. Sneyd J, Carr A, By[CONTACT_66974] W, Bi lski A. A meta -analysis of nausea and vomiting 
following maintenance of anaesthesia with propofol or inhalational agents. European 
Journal of Anaesthesiology| EJA. 1998;15(4):[ADDRESS_73196], Motoyama EK. Clinic al 
characteristics of sevoflurane in children: a comparison with halothane. The Journal 
of the American Society of Anesthesiologists. 1995;82(1):38 -46. 
9. Lerman J, Sikich N, Kleinman S, Yentis S. The pharmacology of sevoflurane in 
infants and children. The Journal of the American Society of Anesthesiologists. 
1994;80(4):814 -824. 
10. Kim T, Niklewski P, Martin J, Obara S, Egan T. Enhancing a sedation score to 
include truly noxious stimulation: the Extended Observer's Assessment of Alertness 
and Sedation (EO AA/S). BJA: British Journal of Anaesthesia. 2015;115(4):569 -577. 
11. Fuentes R, Cortínez I, Ibacache M, Concha M, Muñoz H. Propofol concentration to 
induce general anesthesia in children aged 3 –[ADDRESS_73197]‐site 
model. Pediatric Anesthe sia. 2015;25(6):554 -559. 
12. Xu T, Kurth CD, Yuan I, Vutskits L, Zhu T. An approach to using pharmacokinetics 
and electroencephalography for propofol anesthesia for surgery in infants. Pediatric 
Anesthesia. 2020;30(12):[ADDRESS_73198], Sampson A, Pavone KJ, Brown EN. Clinical Electroencephalography for 
Anesthesiologists: Part I: Background and Basic Signatures. Anesthesiology. 
2015;123(4):[ADDRESS_73199], Ramsay MA, 
Miller TE, McEvoy MD, Gan T J. American Society for Enhanced Recovery and 
Perioperative Quality Initiative joint consensus statement on the role of 
   
21 
 21 
neuromonitoring in perioperative outcomes: electroencephalography. Anesthesia & 
Analgesia. 2020;130(5):1278 -1291.  
15. Yuan I, Xu T, Skow no J, Zhang B, Davidson A, von Ungern -Sternberg BS, 
Sommerfield D, Zhang J, Song X, Zhang M. Isoelectric Electroencephalography in 
Infants and Toddlers During Anesthesia for Surgery -an International Observational 
Study. Anesthesiology. 2022.  
16. FDA. Propo fol FDA 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019627s062lbl.pdf . 
Accessed.  
17. Yuan I, Xu T, Kurth CD. Using Electroencephalography (EEG) to Guide Propofol 
and Sevoflurane Dosing in Pediatric Anesthesia. Anesthesiology Clinics. 
2020;38(3):709 -725. 
18. Hayashi K, Shigemi K, Sawa T. Neonatal electroencephalography shows low 
sensitivity  to anesthesia. Neuroscience letters. 2012;517(2):[ADDRESS_73200] S, Donath S, Frawley G. MAC‐
awake of sevoflurane in children. Pediatric Anesthesia. 2008;18(8):702 -707. 
20. Zbinden A, Maggiorini M, Petersen -Felix S,  Lauber R, Thomson D, Minder C. 
Anesthetic depth defined using multiple noxious stimuli during isoflurane/oxygen 
anesthesia I. Motor reactions. Anesthesiology: The Journal of the American Society 
of Anesthesiologists. 1994;80(2):[ADDRESS_73201] MAC and MAC for intubation after clonidine premedication in children. 
British journal of anaesthesia. 2000;85(5):700 -704. 
22. Dixon W. The up -and-down method for small samples. Journal of the American 
Statistical Association. 1965;60(312):967 -978. 
23. Pace NL, Stylianou MP, Warltier DC. Advances in and limitations of up -and-down 
methodology: a precis of clinical use, study design, and dose estimation in anesthesia 
research. Anesthesiology. 2007;107(1):144 -152. 
24. Görges M, Zhou G, Brant R, Ansermino JM. Sequential allocation trial design in 
anesthesia: an introduction to methods, modeling, and clinical applications. Pediatric 
Anesthesia. 2017;27(3):240 -247. 
25. Kataria BK, Ved SA, Nicodemus  HF, Hoy GR, Lea D, Dubois MY, Mandema JW, 
Shafer SL. The pharmacokinetics of propofol in children using three different data 
analysis approaches. The Journal of the American Society of Anesthesiologists. 
1994;80(1):[ADDRESS_73202] JH, Marks LA, Van Bocxlaer JF, Vereecke H, 
Absalom AR, Struys MM. An evaluation of using population pharmacokinetic 
models to estimate pharmacodynamic parameters for propofol and bispectral index 
in children. The Journal of t he American Society of Anesthesiologists. 
2011;115(1):83 -93. 
27. Absalom A, Amutike D, Lal A, White M, Kenny G. Accuracy of the ‘Paedfusor’in 
children undergoing cardiac surgery or catheterization. British Journal of 
Anaesthesia. 2003;91(4):507 -513. 
   
22 
 22 
28. Rigouzzo A, Girault L, Louvet N, Servin F, De -Smet T, Pi[INVESTIGATOR_136] V, Seeman R, Murat I, 
Constant I. The relationship between bispectral index and propofol during target -
controlled infusion anesthesia: a comparative study between children and young 
adults. Anesthesi a & Analgesia. 2008;106(4):1109 -1116.  
29. Sahinovic MM, Struys MM, Absalom AR. Clinical pharmacokinetics and 
pharmacodynamics of propofol. Clinical pharmacokinetics. 2018;57(12):1539 -1558.  
30. Olbrecht VA, Jiang Y, Viola L, Walter CM, Liu H, Kurth CD. Char acterization of 
the functional near‐infrared spectroscopy response to nociception in a pediatric 
population. Pediatric Anesthesia. 2018;28(2):[ADDRESS_73203]. Determination of the median 
effective concentration (EC50 ) of propofol during oesophagogastroduodenoscopy in 
children. Pediatric Anesthesia. 2001;11(5):549 -553. 
32. Yuan I, Landis WP, Topjian AA, Abend NS, Lang S -S, Huh JW, Kirschen MP, 
Mensinger JL, Zhang B, Kurth CD. Prevalence of isoelectric electroencephalog raphy 
events in infants and young children undergoing general anesthesia. Anesthesia & 
Analgesia. 2020;130(2):462 -471. 
33. Disma N, Veyckemans F, Virag K, Hansen TG, Becke K, Harlet P, Vutskits L, 
Walker SM, de Graaff JC, Zielinska M. Morbidity and mortali ty after anaesthesia in 
early life: results of the European prospective multicentre observational study, 
neonate and children audit of anaesthesia practice in Europe (NECTARINE). British 
Journal of Anaesthesia. 2021;126(6):1157 -1172.  
 